Effect of CsA on plasma lipid parameters in humans
1. Introduction
Cyclosporin A (CsA) is an immunosuppressant drug widely used in organ transplant recipients and patients with auto-immune disorders. Long-term treatment with CsA is associated with hyperlipidemia and an increased risk of atherosclerosis. The mechanisms by which cyclosporin A causes hyperlipidemia are unclear. Cell and animal studies have pointed to various mechanisms that may mediate CsA-induced hyperlipidemia. In this review we will give an overview of CsA-induced hyperlipidemia, with a focus on the data available that might explain the underlying mechanism(s) and describe the available treatment regimes used to treat hyperlipidemia induced by immunosuppressant drugs.
2. Hyperlipidemia in humans after solid organ transplantation
Hyperlipidemia is observed in about 60% of kidney, liver, cardiac and bone marrow transplants after treatment with CsA (for review see [1,2]. There are multiple factors potentially contributing to hyperlipidemia in these patients, such as post-transplantation obesity, multiple drug therapy and diabetes. The concurrent use of steroids in particular, makes it hard to establish a direct contribution of CsA to dyslipidemia in humans, as corticosteroids are known to exacerbate hyperlipidemia in transplant recipients [3,4].
Studies investigating plasma lipids after CsA monotherapy are limited [4,5,6,7,8,9] and only a few studies have directly compared the combination of CsA therapy with low dose prednisolone with other immune suppressing strategies in combination with low dose steroids [10,11]. In general, these studies indicate that CsA treatment can independently lead to elevated plasma triglyceride and cholesterol levels in humans and that these effects are reversible upon cessation of immunosuppression therapy (Table 1). Animal studies (reviewed in [12]), where the effect of CsA can be studied in a more controlled background, indicate that CsA directly raises plasma lipid levels in rats, mice, guinea pigs and rabbits, and have proven that animals are valuable models to study mechanismsof CsA-induced hyperlipidemia.
Monotherapy | Amyotrophic lateral sclerosis | 36 | 2 mnths | TC (21%) LDL-C (31%) apoB (12%) TG = HDL = | [5] |
Monotherapy | Autologous bone marrow transplants | 13 | 32 days | TC (26%) LDL-C HDL-C TG = VLDL-C = | [13] |
Monotherapy | Renal transplants | 59 | 3-6 and 12 mnths | TC = LDL-C = apoB TG HDL-C apoA-I | [8] |
Monotherapy | Renal transplants | 58 | "/>1 yr | TC LDL-C apoB TG VLDL-C = HDL-C HDL2-C = HDL3-C | [14] |
Monotherapy and CsA/pred | Bone marrow transplants | 180 | 100 days | TC LDL-C apoB TG VLDL-trig VLDL-C = HDL HDL2 HDL3 = apoA-I | [4] |
Monotherapy | Psoriasis | 15 | 3 mnths | TC (22%) LDL-C (35%) TG = VLDL-C = HDL-C = | [9] |
ALG/aza/cortv CsA/ALG/aza/cort | Renal transplants | 702 | 52 wks | TC (20%) LDL-C TG HDL-C = | [7] |
Aza/pred v CsA v CsA/pred | Renal transplants | 9 | 3 mnths | TC LDL-C (45%) TG = VLDL-C = HDL-C = | [6] |
Aza/pred v CsA/pred | Renal transplants | 20 | 7.7 yrs | TC LDL-C apoB TG VLDL-C HDL-C | [10] |
2.1. Plasma VLDL
Triglyceride-containing VLDL particles are produced in the liver via lipidation of apolipoprotein B (apoB) by microsomal triglyceride transfer protein (MTP), generating triglyceride-poor (VLDL2) as well as triglyceride-rich VLDL (VLDL1) particles, both of which can be secreted [15]. In plasma, VLDL is converted to intermediate-density lipoprotein (IDL) by lipoprotein lipase (LPL). IDL can be further hydrolyzed by lipases to low density lipoprotein (LDL). CsA increases plasma VLDL levels in transplant recipients and a concomitant increase in plasma apoB levels is observed [4,10,11]. It is unclear whether both plasma VLDL1 and VLDL2 levels are elevated. In contrast to LDL levels, plasma triglyceride and VLDL levels appear to increase only after long-term treatment with CsA (Table 1 and [8])
Hypertriglyceridemia in transplant patients is associated with increased plasma apolipoprotein CIII (apoCIII) levels [16,17,18] and decreased lipase activity (see below). As apoCIII inhibits LPL and hepatic lipase (HL) as well as uptake of triglyceride lipoprotein in liver, the increase of apoCIII may be an important contributor to hypertriglyceridemia found in transplant patients.
2.2. Plasma LDL
Plasma LDL levels appear to be consistently elevated by CsA [4,5,6,7,9,10,13,14] even in patients where plasma VLDL levels are not altered [5,6,9,13]. A correlation between CsA levels and plasma LDL-C has been described in some studies [19], but was not observed in others [5,20]. Regulation of plasma LDL levels is complex, depending on hepatic VLDL production, subsequent lipolysis of VLDL, clearance of LDL via the LDL receptor (LDLr) in the liver and conversion into bile. CsA may affect LDL metabolism at several levels (section 3.2).
2.3. Plasma HDL
Total plasma HDL levels are inversely correlated with the risk of cardiovascular disease [21]. HDL particles are however heterogeneous in size and composition, and occur as HDL2a, HDL2b, HDL3a, HDL3b and HDL3c which are progressively smaller in diameter and contain higher protein to lipid ratios. The precise contribution of various HDL subclasses to cardiovascular disease is currently unclear [21,22]. Plasma HDL cholesterol levels are determined by production of nascent HDL particles in the liver and intestine,by plasma transfer reactions of lipids between HDL and lipolysed triglyceride lipoproteins such as VLDL or chylomicrons,hepatic uptake of HDL lipids via the scavenger receptor class B1 (SRB1) HDL receptor in the liver, and renal clearance of small, lipid-poor apoA-I particles. Nascent HDL particles are formed by lipidation of apolipoprotein A-I (apoA-I) via the ATP-binding cassette transporter-1 (ABCA1) located in cellular membranes, although ABCA1-independent pathways of apoA-I lipidation also exist [23]. The formed lipid-poor HDL particles acquire more lipid after interaction with ABCG1 and mature by the subsequent esterification of cholesterol by lecithin-acyl transferase (LCAT). Further remodeling occurs by phospholipid transfer protein (PLTP) generating HDL2. HDL2 can be converted into HDL3 by hydrolysis via lipases and by transfer of cholesteryl esters to triglyceride-containing lipoproteins with the reciprocal exchange for triglycerides, which is mediated by cholesteryl ester transfer protein (CETP).
Immunosuppressive therapy has been reported to increase, decrease or leave HDL levels unaffected [5,10,11,24]. Parallel changes in plasma apoA-I levels are usually observed. Increased HDL levels are observed in most transplant patients, but this is most likely related to the concomitant treatment with steroids, which are known to increase plasma HDL [3]. CsA may affect particular subclasses of HDL more than others. Independently of steroids, plasma HDL levels, especially the HDL3 subpopulation, were found to inversely relate to plasma CsA levels [19].In a study of bone marrow transplant recipients CsA decreased total plasma HDL, and in particular HDL2 [4]. In rats, a similar decrease in plasma HDL and HDL2 levels was observed after CsA treatment [25]. A recent study performed in pediatric renal transplant recipients showed that although total plasma HDL levels were not changed with CsA treatment, the relative proportion of HDL2b decreased while the relative proportion of HDL3a, HDL3b and HDL3c increased [26]. This is important as decreased HLD2b with increased HDL3b is associated with an atherogenic lipoprotein phenotype characterized by increased triglycerides and small dense LDL [27]. This result also emphases that simple monitoring of total HDL cholesterol may be insufficient to understand the consequences of CsA on HDL biology.
2.4. Plasma lipoprotein (a)
Lipoprotein (a) [Lp(a)] is a LDL-like lipoprotein consisting of LDL with one molecule of apoB covalently linked to a molecule of apolipoprotein (a). Plasma Lp(a) levels, and especially certain genetic Lp(a) variants, are independently associated with an increased risk for CVD [28,29]. Elevated Lp(a) plasma levels have been observed in renal transplant studies [14,30] this was however, not observed by others [31]. Although some studies suggested normalization of elevated Lp(a) levels after successful transplantation due to improved kidney function [31,32], CsA treatment has been indicated to independently increase Lp(a) levels in renal transplant recipients [8,14,33]. The mechanisms by which CsA affect plasma Lp(a) levels are unexplored, but may involve similar mechanisms to that of elevation of plasma LDL levels. As the LDLr does not play a major role in the clearance of Lp(a), the mechanism however, is unlikely mediated via effects of CsA on the LDLr (see section 3.2.1).
2.5. Qualitative differences in lipoproteins
2.5.1.Particle. changes
Elevated plasma triglyceride levels are associated with the formation of triglyceride rich LDL particles that are more atherogenic [34]. A high prevalence of smaller denser LDL particles is observed in transplant recipients [35] and appears to be associated with CsA therapy [26,36]. Inhibition of lipoprotein lipase (LPL) activity is associated with the formation of small dense LDL subclasses. As apoCIII inhibits lipase activity, increased plasma apoCIII levels observed with CsA-treatment may explain inhibited lipase activity and subsequent increase in small dense LDL particles [17]. In addition decreased lipase activity could contribute to decreased HDL2 subclassesobserved, while effects on CETP by CsA may help explain increases in HDL3 subfractions (see section 2.3 and 3.1.2).
2.5.2. Interaction of CsA with plasma lipoproteins
In whole blood CsA is primarily transported bound to lipoproteins (33%) and erythrocytes (58%)and whole blood CsA levels correlate with lipoprotein levels [37,38].
Concerns have been raised about changes to the bioavailabilty and activity of CsA resulting from its binding to lipoproteins, especially as decreased CsA activity and increased toxicity have been observed in patients with hyperlipidemia [42,44]. CsA levels are higher in hyperlipidemic patients due to decreased clearance which was reversed after lipid-lowering with fibrates (reviewed in [37]).
3. Mechanisms of CsA-Induced hyperlipidemia – What we learn from cell and animal studies
As the effects of CsA in humans are confounded by many factors such as other medication, obesity, insulin resistance and nutritional status, cell and animal studies are useful to elucidate the mechanism(s) of CsA-induced hyperlipidemia. Figure 1 depicts the reported CsA-effects on VLDL, LDL and HDL metabolism.
3.1. VLDL
3.1.1. Effects of CsA on VLDL synthesis and secretion
CsA decreased apoB translocation over the endoplasmic reticulum (ER) membrane in the human liver cell line HepG2 [47]. It was suggested that this was due to a reduction in the efficiency of lipid transfer by inhibition of MTP, however whether MTP activity is inhibited by CsA was not investigated. These findings are in line with the report from Kaptein et al. [48], which showed that CsA inhibits VLDL and apoB secretion from HepG2 cells, by post-translational mechanisms. In contrast, in mice, CsA increased the rate of hepatic VLDL secretion
3.1.2. VLDL metabolism
Inhibition of lipolysis by CsA could contribute to increased plasma VLDL and reduced HDL concentrations. Various studies have investigated lipase activity in patients, but results may be confounded by co-treatment with steroids. HL activity was increased in cardiac transplant patients and correlated with CsA dose while lipoprotein lipase (LPL) activity was decreased in these patients [51]. Others have shown decreased HL as well as LPL activity in kidney transplant recipients [52]. More directly, Tory et al [53] showed suppression of LPL activity in plasma from normolipidemic subjects treated with CsA, while in rats, CsA dose- and time-dependent decreased plasma LPL activity [24]. In addition, LPL abundance in skeletal muscle and adipose tissue was decreased in rats [50]. These latter studies suggested CsA can inhibit LPL activity independently of steroids. Although the precise mechanism of CsA-inhibited LPL activity is unknown, it helps to explain increased triglyceride levels observed after CsA treatment.
Some studies show reduced cholesteryl ester transfer protein (CETP) activity in transplant recipients [54]. In contrast, CsA directly added to human plasma
3.2. LDL
3.2.1. LDL synthesis and catabolism
We have recently reviewed this literature in detail [55]. There appear to be conflicting conclusions arising from
3.3. HDL
CsA effects on plasma HDL and HDL subclasses may be mediated by effects on the synthesis and/or formation of HDL as well as by effecting remodeling of HDL through changes inlipase and/or CETP activity (see 3.1.2)
3.3.1. Effect of CsA on HDL synthesis and formation
Direct effects of CsA on the expression of ABCA1 and apoA-I have also been reported and may contribute to the changes in HDL formation. The target of immunosuppression by CsA, Nuclear Factor of activated T-cells, cytoplasmic 2 (NFATc2), was found to bind the mouse ABCA1 promoter and mediate CsA-inhibition of ABCA1 expression by inflammatory stimuli [63]. In addition CsA has been found to inhibit apoA-I gene expression in human HepG2 cells and rats [64]. A recent proteomic study in HepG2 cells showed that CsA decreased secretion levels of apoA-I suggesting that the transcriptional effects of CsA on apoA-I expression may lead to decreased amounts of secreted apoA-I [65].
3.3.2. Effects on HDL metabolism
As mentioned above (section 3.1.2), CsA directly suppresses LPL activity and increases CETP activity in human plasma and animals (section 3.1.2). LPL activity is strongly associated with plasma HDL2 concentrations [66], and decreased LPL levels in CsA treatment may therefore contribute to decreased HDL2 levels [4,25]. On the other hand, increased CETP activity will generate triglyceride-rich HDL, which is converted to smaller HDL3 particles by HL [66].
3.5. Effects on bile acid synthesis and secretion
3.5.1. Effects on bile synthesis
In liver, cholesterol is converted to bile acids by 7-hydroxylase (CYP7) or 27-hydroxylase (CYP27A1) [67]. In healthy humans, CYP7α is considered the predominantly pathway while CYP27A1 accounts for 10% of bile acid synthesis and subsequent formation of chenodeoxycholate. However inhibition of Cyp7α can increase the contribution of the CYP27A1 pathway [68].
The effects of CsA on CYP27A1 may relate to effects of CsA on cholesterol metabolism. 27-hydroxycholesterol is a potent negative feedback regulator of HMG-CoA reductase [74] and decreased CYP27A1 activity may therefore explain increased HMG-CoA reductase mRNA and cholesterol levels [57]. Although important in macrophages, it should be noted however that it is not clear whether such a feedback loop exists in liver cells [75]. Increased cholesterol synthesis could subsequently lead to downregulation of LDLr levels as observed in some CsA studies, also contributing to increased plasma cholesterol levels (see section 3.2.1).
Besides effects on bile acid synthesis CsA may affect bile flow. CsA treatment is associated with increased plasma bile acid concentrations and cholestasis in humans as well as in animal models [9,52,76]. Studies in rat indicate that bile flow and the secretion of bile salts, proteins and lipids into the bile are dose-dependently inhibited by CsA [52,76,77]. Interestingly, the changes in serum levels of bile acids are consistent with CsA-mediated inhibition of hepatocellular uptake of individual bile acids [78,79]. The inhibitory effect was greater for phosholipid secretion than that for cholesterol [80] and in some studies no inhibition of cholesterol excretion was observed [81], suggesting differential effects on transport mechanisms. Transport pumps involved in bile synthesis and secretion belong to the family of the ATP-binding cassette transporters which include, multidrug resistance proteins (MDR) and P-glycoprotein, and most of which are effectively inhibited by CsA [79,82]. Interestingly, comparison of the bile salt export pump (BSEP) activity from different species, showed that CsA inhibits bile salt transport with species and bile salt specific variation [83]. Rat BSEP was for example more effectively inhibited than mouse BSEP. Biliary cholesterol secretion is mediated via ABCG5 and ABCG8 [84]. Although both members of the ATP-binding cassette family, it has not been investigated whether CsA inhibits ABCG5/8 activity. As phospholipids are transported via MDR3, it is likely that differences in efficacy of CsA between inhibition of MRD3 and ABCG5/8 exist. It is clear that CsA can affect bile flow and secretion in cultured cells and animal models. It should be noted however, that in humans no inhibitory effect of CsA on secretion of bile acids and lipids or on bile composition after liver transplantation was observed [85]. Others have shown that although cholate synthesis was reduced by CsA, compensatory increased intestinal absorption counteracted this decrease [86]. It remains therefore unclear to what extent inhibition of bile flow and secretion by CsA are contributing to hypercholesteremia
4. Therapies to address hyperlipidemia
Hyperlipidemia is associated with significant morbidity and mortality rates in transplant recipients [87]. Many strategies have been investigated to target dyslipidemia in transplant patients. A number of excellent comprehensive reviews have been published on the clinical management of hyperlipidemia and its risks (eg [88,89]). We will therefore restrict our comments to a very brief summary of this area.
4.1. Statins
Statins inhibit HMG-CoA reductase, the rate limiting enzyme in the cholesterol synthesis pathway and are world-wide the drug of choice to lower plasma LDL-C levels. Various statins have been tested in transplant patients and all show significant lowering of plasma cholesterol, LDL-C and apoB levels with some indicating improved survival rates (for review see [88,89,90]). A randomized trial, investigating the safety and efficacy of statins in renal transplant patients, the Assessment of LEscol in Renal Transplantation (ALERT) study, showed that fluvastatin effectively lowered LDL-C by 32% and reduced cardiac death and non-fatal myocardial infarction incidence significantly [91]. Importantly, statins may provide beneficial effects other then their lipid-lowering properties [92]. Wissing et al [93] reported improved flow mediated brachial artery vasodilatation by atorvastatin in kidney transplant patients and significant reductions in acute rejections have been observed in cardiac transplant patients [94].
Rhabdomyolysis, one of the few serious side effects of statins, is more common with high dose statin treatment. The risk is elevated in patients with renal disease and in patients taking drugs affecting statin metabolism, especaily in those taking CsA [88,89]. All statins have the potential to interact with CsA, as CsA substantially increases plasma levels of all statins. Although this is most notable for those metabolized via the Cyp3A4 pathway, statins not metabolized via the Cyp3A4 pathway [95] such as pravastatin and fluvastatin are also affected [95], suggesting that the interaction of CsA and statins may involve other mechanisms such as inhibition of drug transporters. Simvastatin poses the highest risk of myopathy, and particular care must be taken with higher doses of this agent, with recommendations that doses of 10mg/d are not exceeded in transplant patients [89]. Because statin therapy has been associated with mortality benefit after transplantation, correction of hyperlipidemia using lower doses of statins is mandatory after transplantation. Therefore careful clinical monitoring of patients as well as measurement of creatine kinase levels to detect muscle injury is advised, and the use of statins that are not metabolized via CYP3A4, such as fluvastatin or pravastatinmay be preferential [95].
4.2. Fibrates
Fibrates lower plasma triglyceride levels via activation of the Peroxisome Proliferator Activated Receptor alpha (PPARα) and may be useful in transplant patients with elevated plasma triglycerides especially in combination with statin treatment to lower plasma cholesterol levels. Gemfibrozil was found to significantly lower plasma triglyceride levels in heart transplant patients and increase long term survival [96,97]. Fenofibrate is less well studied in transplant patients and may be associated with increased nephrotoxicity [88,98]. Care must be taken administering fibrates with CsA, particularly in combination with statins as drug-drug interactions exist via CYP3A4 as well as the hepatic uptake transporter the organic anion transporting polypeptide 1B1 (OAT1B1).
4.3. Ezetimibe
Inhibition of intestinal cholesterol absorption to lower high plasma cholesterol levels may be used when statins or fibrates are ineffective or are not tolerated. Ezetimibe proved to be an effective drug lowering plasma LDL-C levels significantly by blocking cholesterol absorption in the small intestine [99]. To that point though, various studies showed effective LDL-C lowering in liver, cardiac and renal transplant recipients [99]. Although, drug-drug interaction between CsA and ezetimibe were suggested (See [88]), CsA levels in studied transplant patients were not affected by combined ezetimibe use (reviewed in [99]). Co-administration of ezetimibe with (low-dose) statins has been found to effectively reduce high plasma cholesterol levels in transplant recipients and may be useful in patients that resistant to high-dose statin or where target plasma lipid levels can not be achieved by statin therapy alone [100,101].
5. Conclusions
CsA-induced hyperlipidemia is well established and remains a significant clinical issue. CsA potentially affects many aspects of lipid and lipoprotein metabolism and the precise underlying mechanism(s) causing dyslipidemia are still unclear. Further mechanistic studies may lead to the generation immunosuppressants that do not cause hyperlipidemia or may help to develop strategies to effectively target CsA-induced hyperlipidemia.
References
- 1.
Kobashigawa JA, Kasiske BL 1997 Hyperlipidemia in solid organ transplantation. Transplantation63 331 338 - 2.
Miller LW 2002 Cardiovascular toxicities of immunosuppressive agents. Am J Transplant2 807 818 - 3.
Strohmayer EA, Krakoff LR 2011 Glucocorticoids and cardiovascular risk factors. Endocrinol Metab Clin North Am40 409 417 ix. - 4.
Lopez-Miranda J. Perez-Jimenez F. Torres A. Espino-Montoro A. Gomez P. et al. 1992 Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem25 379 386 - 5.
Ballantyne C. M. Podet E. J. Patsch W. P. Harati Y. Appel V. et al. 1989 Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA262 53 56 - 6.
Raine A. E. Carter R. Mann J. I. Morris P. J. 1988 Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant3 458 463 - 7.
Kasiske BL, Tortorice KL, Heim-Duthoy KL, Awni WM, Rao KV 1991 The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis17 700 707 - 8.
Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA 1995 The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol5 2073 2081 - 9.
BD Edwards Bhatnagar. D. Mackness M. I. Gokal R. Ballardie F. W. et al. 1995 Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. QJM88 109 113 - 10.
Schorn T. F. Kliem V. Bojanovski M. Bojanovski D. Repp H. et al. 1991 Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients. Transpl Int4 92 95 - 11.
Ichimaru N. Takahara S. Kokado Y. JD Wang Hatori. M. et al. 2001 Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis158 417 423 - 12.
Kockx M. Guo D. L. Traini M. Gaus K. Kay J. et al. 2009 Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway. J Biol Chem284 24144 24154 - 13.
Luke D. R. Beck J. E. Vadiei K. Yousefpour M. Le Maistre C. F. et al. 1990 Longitudinal study of cyclosporine and lipids in patients undergoing bone marrow transplantation. J Clin Pharmacol30 163 169 - 14.
Brown J. H. Anwar N. Short C. D. Bhatnager D. Mackness M. I. et al. 1993 Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant8 863 867 - 15.
Adiels M. Olofsson S. O. Taskinen M. R. Boren J. 2008 Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol28 1225 1236 - 16.
Kimak E. Solski J. Baranowicz-Gaszczyk I. Ksiazek A. 2006 A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients. Ren Fail28 483 486 - 17.
Badiou S. Garrigue V. Dupuy A. M. Chong G. Cristol J. P. et al. 2006 Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? Transplant Proc38 2314 2316 - 18.
MD Tur Garrigue. V. Vela C. Dupuy A. M. Descomps B. et al. 2000 Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplant Proc32 2783 2784 - 19.
Kuster G. M. Drexel H. Bleisch J. A. Rentsch K. Pei P. et al. 1994 Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation57 1479 1483 - 20.
Ramezani M. Einollahi B. Ahmadzad-Asl M. Nafar M. Pourfarziani V. et al. 2007 Hyperlipidemia after renal transplantation and its relation to graft and patient survival. Transplant Proc39 1044 1047 - 21.
Kontush A. MJ Chapman 2006 Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev58 342 374 - 22.
Rosenson R. S. Brewer H. B. Jr MJ Chapman Fazio. S. MM Hussain et. al 2011 HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem57 392 410 - 23.
Zheng H. Kiss R. S. Franklin V. MD Wang Haidar. B. et al. 2005 ApoA-I lipidation in primary mouse hepatocytes. Separate controls for phospholipid and cholesterol transfers. J Biol Chem280 21612 21621 - 24.
Lopez-Miranda J. Perez-Jimenez F. Gomez-Gerique J. A. Espino-Montoro A. Hidalgo-Rojas L. et al. 1992 Effect of cyclosporin on plasma lipoprotein lipase activity in rats. Clin Biochem25 387 394 - 25.
Espino A. Lopez-Miranda J. Blanco-Cerrada J. Zambrana J. L. MA Aumente et. al 1995 The effect of cyclosporine and methylprednisolone on plasma lipoprotein levels in rats. J Lab Clin Med125 222 227 - 26.
Zeljkovic A. Vekic J. Spasojevic-Kalimanovska V. Jelic-Ivanovic Z. Peco-Antic A. et al. 2011 Characteristics of low-density and high-density lipoprotein subclasses in pediatric renal transplant recipients. Transpl Int24 1094 1102 - 27.
Berneis KK, Krauss RM 2002 Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res43 1363 1379 - 28.
Erqou S. Kaptoge S. Perry P. L. Di Angelantonio E. Thompson A. et al. 2009 Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA302 412 423 - 29.
Clarke R. Peden J. F. Hopewell J. C. Kyriakou T. Goel A. et al. 2009 Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med361 2518 2528 - 30.
Fonseca I. Queiros J. Costa S. MJ Santos Henriques. A. C. et al. 2002 Lipoprotein(A) in renal transplant recipients. Transplant Proc34 370 372 - 31.
Innocenti M. Lorenzetti M. Naldi F. Paleologo G. Pasquariello A. et al. 1998 Evaluation of lipoprotein A in renal transplant recipients. Transplant Proc 30:2048 EOF - 32.
Black IW, Wilcken DE 1992 Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem38 353 357 - 33.
Webb A. T. Reaveley D. A. O’Donnell M. O’Connor B. Seed M. et al. 1993 Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet341 268 270 - 34.
Packard C. J. Shepherd J. 1997 Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol17 3542 3556 - 35.
Rajman I. Harper L. Mc Pake D. MJ Kendall Wheeler. D. C. 1998 Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant13 2281 2287 - 36.
Quaschning T. Mainka T. Nauck M. Rump L. C. Wanner C. et al. 1999 Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int Suppl 71: S235 237 - 37.
Akhlaghi F. Trull A. K. 2002 Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet41 615 637 - 38.
Gardier A. M. Mathe D. Guedeney X. Barre J. Benvenutti C. et al. 1993 Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporin A. Ther Drug Monit15 274 280 - 39.
Sgoutas D. Mac Mahon. W. Love A. Jerkunica I. 1986 Interaction of cyclosporin A with human lipoproteins. J Pharm Pharmacol38 583 588 - 40.
Rifai N. Chao F. F. Pham Q. Thiessen J. Soldin S. J. 1996 The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines. Clin Biochem29 149 155 - 41.
Wasan K. M. Pritchard P. H. Ramaswamy M. Wong W. Donnachie E. M. et al. 1997 Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm Res14 1613 1620 - 42.
De Klippel N. Sennesael J. Lamote J. Ebinger G. de Keyser J. 1992 Cyclosporin leukoencephalopathy induced by intravenous lipid solution. Lancet 339: 1114. - 43.
Akhlaghi F. Mc Lachlan A. J. Keogh A. M. Brown K. F. 1997 Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol44 537 542 - 44.
de Groen P. C. Aksamit A. J. Rakela J. Forbes G. S. Krom R. A. 1987 Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med317 861 866 - 45.
Wasan K. M. Ramaswamy M. Kwong M. Boulanger K. D. 2002 Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A. AAPS PharmSci 4:E30 EOF 101 EOF - 46.
Lemaire M. Pardridge W. M. Chaudhuri G. 1988 Influence of blood components on the tissue uptake indices of cyclosporin in rats. J Pharmacol Exp Ther244 740 743 - 47.
Macri J. Adeli K. 1997 Studies on intracellular translocation of apolipoprotein B in a permeabilized HepG2 system. J Biol Chem272 7328 7337 - 48.
Kaptein A. de Wit E. C. Princen H. M. 1994 Cotranslational inhibition of apoB-100 synthesis by cyclosporin A in the human hepatoma cell line HepG2. Arterioscler Thromb14 780 789 - 49.
Wu J. Zhu Y. H. Patel S. B. 1999 Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2. Am J Physiol 277: E1087 1094 - 50.
Vaziri N. D. Liang K. Azad H. 2000 Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. J Pharmacol Exp Ther294 778 783 - 51.
Superko HR, Haskell WL, Di Ricco CD 1990 Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation. Am J Cardiol66 1131 1134 - 52.
Deters M. Kirchner G. Koal T. Resch K. Kaever V. 2004 Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig Dis Sci49 30 37 - 53.
Tory R. Sachs-Barrable K. Hill J. S. Wasan K. M. 2008 Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma. Int J Pharm358 219 223 - 54.
Atger V. Leclerc T. Cambillau M. Guillemain R. Marti C. et al. 1993 Elevated high density lipoprotein concentrations in heart transplant recipients are related to impaired plasma cholesteryl ester transfer and hepatic lipase activity. Atherosclerosis103 29 41 - 55.
Kockx M. Jessup W. Kritharides L. 2010 Cyclosporin A and atherosclerosis--cellular pathways in atherogenesis. Pharmacol Ther128 106 118 - 56.
Rayyes O. A. Wallmark A. Floren C. H. 1996 Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%. Hepatology24 613 619 - 57.
Gueguen Y. Ferrari L. Souidi M. Batt A. M. Lutton C. et al. 2007 Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase. Basic Clin Pharmacol Toxicol100 392 397 - 58.
Lopez-Miranda J. Vilella E. Perez-Jimenez F. Espino A. Jimenez-Pereperez J. A. et al. 1993 Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism42 678 683 - 59.
Le Goff W. Peng D. Q. Settle M. Brubaker G. Morton R. E. et al. 2004 Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I. Arterioscler Thromb Vasc Biol24 2155 2161 - 60.
Lorenzi I. von Eckardstein. A. Cavelier C. Radosavljevic S. Rohrer L. 2008 Apolipoprotein A-I but not high-density lipoproteins are internalised by RAW macrophages: roles of ATP-binding cassette transporter A1 and scavenger receptor BI. J Mol Med86 171 183 - 61.
Karwatsky J. Ma Dong L. Zha F. X. 2009 Cholesterol efflux to apoA-I in ABCA1 expressing cells is regulated by Ca2+ dependent-calcineurin signaling. J Lipid Res. - 62.
Emeson EE, Shen ML 1993 Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am J Pathol142 1906 1915 - 63.
Maitra U. Parks J. S. Li L. 2009 An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2. Mol Cell Biol29 5989 5997 - 64.
Zheng XL, Wong NC 2006 Cyclosporin A inhibits apolipoprotein AI gene expression. J Mol Endocrinol37 367 373 - 65.
Van Summeren A. Renes J. Bouwman F. G. Noben J. P. van Delft J. H. et al. 2011 Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci120 109 122 - 66.
von Eckardstein. A. Huang Y. Assmann G. 1994 Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol5 404 416 - 67.
Anderson K. E. Kok E. Javitt N. B. 1972 Bile acid synthesis in man: metabolism of 7-hydroxycholesterol- 14 C and 26-hydroxycholesterol- 3 H. J Clin Invest51 112 117 - 68.
Duane WC, Javitt NB 1999 hydroxycholesterol: production rates in normal human subjects. J Lipid Res40 1194 1199 - 69.
Souidi M. Parquet M. Ferezou J. Lutton C. 1999 Modulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase activities by steroids and physiological conditions in hamster. Life Sci64 1585 1593 - 70.
Princen H. M. Meijer P. Wolthers B. G. Vonk R. J. Kuipers F. 1991 Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis. Biochem J 275 ( Pt 2):501 EOF 5 EOF - 71.
Winegar DA, Salisbury JA, Sundseth SS, Hawke RL 1996 Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells. J Lipid Res37 179 191 - 72.
Segev H. Honigman A. Rosen H. Leitersdorf E. 2001 Transcriptional regulation of the human sterol 27-hydroxylase gene (CYP27) and promoter mapping. Atherosclerosis156 339 347 - 73.
Hulzebos C. V. Bijleveld C. M. Stellaard F. Kuipers F. Fidler V. et al. 2004 Cyclosporine A-induced reduction of bile salt synthesis associated with increased plasma lipids in children after liver transplantation. Liver Transpl10 872 880 - 74.
Esterman A. L. Baum H. Javitt N. B. Darlington G. J. 1983 hydroxycholesterol: regulation of hydroxymethylglutaryl-CoA reductase activity in Chinese hamster ovary cell culture. J Lipid Res24 1304 1309 - 75.
Javitt NB 2002 R,26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles. J Lipid Res43 665 670 - 76.
Stone B. G. Udani M. Sanghvi A. Warty V. Plocki K. et al. 1987 Cyclosporin A-induced cholestasis. The mechanism in a rat model. Gastroenterology93 344 351 - 77.
Roman I. D. MJ Monte-Buitrago Gonzalez. Esteller J. M. Jimenez A. R. 1990 Inhibition of hepatocytary vesicular transport by cyclosporin A in the rat: relationship with cholestasis and hyperbilirubinemia. Hepatology12 83 91 - 78.
Azer SA, Stacey NH 1994 Differential effects of cyclosporin A on transport of bile acids by rat hepatocytes: relationship to individual serum bile acid levels. Toxicol Appl Pharmacol124 302 309 - 79.
Stieger B. Fattinger K. Madon J. Kullak-Ublick G. A. Meier P. J. 2000 Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology118 422 430 - 80.
Galan A. I. Roman I. D. ME Munoz Cava. F. Gonzalez-Buitrago J. M. et al. 1992 Inhibition of biliary lipid and protein secretion by cyclosporine A in the rat. Biochem Pharmacol44 1105 1113 - 81.
Chan FK, Shaffer EA 1997 Cholestatic effects of cyclosporine in the rat. Transplantation63 1574 1578 - 82.
Bohme M. Jedlitschky G. Leier I. Buchler M. Keppler D. 1994 ATP-dependent export pumps and their inhibition by cyclosporins. Adv Enzyme Regul34 371 380 - 83.
Kis E. Ioja E. Nagy T. Szente L. Heredi-Szabo K. et al. 2009 Effect of membrane cholesterol on BSEP/Bsep activity: species specificity studies for substrates and inhibitors. Drug Metab Dispos37 1878 1886 - 84.
Yu L. Gupta S. Xu F. Liverman A. D. Moschetta A. et al. 2005 Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem280 8742 8747 - 85.
Baiocchi L. Angelico M. De Luca L. Ombres D. Anselmo A. et al. 2006 Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the first 3 months after liver transplant in humans. Transpl Int19 389 395 - 86.
Hulzebos C. V. Wolters H. Plosch T. Kramer W. Stengelin S. et al. 2003 Cyclosporin a and enterohepatic circulation of bile salts in rats: decreased cholate synthesis but increased intestinal reabsorption. J Pharmacol Exp Ther304 356 363 - 87.
Toussaint C. Kinnaert P. Vereerstraeten P. 1988 Late mortality and morbidity five to eighteen years after kidney transplantation. Transplantation45 554 558 - 88.
Bilchick K. C. CA Henrikson Skojec. D. Kasper E. K. Blumenthal R. S. 2004 Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J148 200 210 - 89.
Ballantyne C. M. Corsini A. Davidson M. H. Holdaas H. Jacobson T. A. et al. 2003 Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med163 553 564 - 90.
Ojo AO 2006 Cardiovascular complications after renal transplantation and their prevention. Transplantation82 603 611 - 91.
Holdaas H. Fellstrom B. Jardine A. G. Holme I. Nyberg G. et al. 2003 Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet361 2024 2031 - 92.
Blum A. Shamburek R. 2009 The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis203 325 330 - 93.
Wissing K. M. Unger P. Ghisdal L. Broeders N. Berkenboom G. et al. 2006 Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation82 771 778 - 94.
Kobashigawa J. A. Katznelson S. Laks H. Johnson J. A. Yeatman L. et al. 1995 Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med333 621 627 - 95.
Asberg A. 2003 Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. Drugs63 367 378 - 96.
Pflugfelder P. W. Huff M. Oskalns R. Rudas L. Kostuk W. J. 1995 Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant14 613 622 - 97.
Stapleton D. D. Mehra M. R. Dumas D. Smart F. W. Milani R. V. et al. 1997 Lipid-lowering therapy and long-term survival in heart transplantation. Am J Cardiol80 802 805 - 98.
Boissonnat P. Salen P. Guidollet J. Ferrera R. Dureau G. et al. 1994 The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation58 245 247 - 99.
Pharmacol RepSuchy D. Labuzek K. Stadnicki A. Okopien B. Ezetimibe--a new. approach in. hypercholesterolemia management. 63 1335 1348 - 100.
Yoon HE, Song JC, Hyoung BJ, Hwang HS, Lee SY, et al. 2009 The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Korean J Intern Med24 233 237 - 101.
Lopez V. Gutierrez C. Gutierrez E. Sola E. Cabello M. et al. 2008 Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia. Transplant Proc40 2925 2926